<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ATP-binding cassette transporter A1 (ABCA1) mediates the rate-limiting step in <z:chebi fb="6" ids="39025">high density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) particle formation, and its expression is regulated primarily by <z:chebi fb="0" ids="53030">oxysterol</z:chebi>-dependent activation of liver X receptors </plain></SENT>
<SENT sid="1" pm="."><plain>We previously reported that ABCA1 expression and <z:chebi fb="17" ids="39025">HDL</z:chebi> formation are impaired in the lysosomal cholesterol storage disorder <z:e sem="disease" ids="C0028064" disease_type="Disease or Syndrome" abbrv="">Niemann-Pick disease</z:e> type C1 and that plasma <z:chebi fb="0" ids="47775">HDL-C</z:chebi> is low in the majority of <z:e sem="disease" ids="C0028064" disease_type="Disease or Syndrome" abbrv="">Niemann-Pick disease</z:e> type C patients </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we show that ABCA1 regulation and activity are also impaired in cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> <z:e sem="disease" ids="C0267971" disease_type="Disease or Syndrome" abbrv="">storage disease</z:e> (CESD), caused by mutations in the LIPA gene that result in less than 5% of <z:mpath ids='MPATH_458'>normal</z:mpath> lysosomal acid lipase (LAL) activity </plain></SENT>
<SENT sid="3" pm="."><plain>Fibroblasts from patients with CESD showed impaired up-regulation of ABCA1 in response to <z:chebi fb="2" ids="39026">low density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) loading, reduced <z:chebi fb="0" ids="16247">phospholipid</z:chebi> and cholesterol efflux to <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A-I, and reduced Î±-<z:chebi fb="17" ids="39025">HDL</z:chebi> particle formation </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment of <z:mpath ids='MPATH_458'>normal</z:mpath> fibroblasts with <z:chebi fb="3" ids="3638">chloroquine</z:chebi> to inhibit LAL activity reduced ABCA1 expression and activity, similar to that of CESD cells </plain></SENT>
<SENT sid="5" pm="."><plain>Liver X receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> treatment of CESD cells corrected ABCA1 expression but failed to correct <z:chebi fb="15" ids="39026">LDL</z:chebi> cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> hydrolysis and cholesterol efflux to apoA-I </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="15" ids="39026">LDL</z:chebi>-induced production of 27-hydroxycholesterol was reduced in CESD compared with <z:mpath ids='MPATH_458'>normal</z:mpath> fibroblasts </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with conditioned medium containing LAL from <z:mpath ids='MPATH_458'>normal</z:mpath> fibroblasts or with recombinant human LAL rescued ABCA1 expression, apoA-I-mediated cholesterol efflux, <z:chebi fb="17" ids="39025">HDL</z:chebi> particle formation, and production of 27-hydroxycholesterol by CESD cells </plain></SENT>
<SENT sid="8" pm="."><plain>These results provide further evidence that the rate of release of cholesterol from late endosomes/lysosomes is a critical regulator of ABCA1 expression and activity, and an explanation for the <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> seen in CESD patients </plain></SENT>
</text></document>